Drug Approval | January 24, 2026
Sun Pharma gets DCGI nod to launch generic Semaglutide injection for weight loss in India
Company to launch product after the expiry of semaglutide patent in India
Company to launch product after the expiry of semaglutide patent in India
Lupin’s double ‘A’ rating in Climate and Water exemplifies its steadfast commitment to sustainability
The company has posted net profit of Rs. 4,064.9 crore for the 9 months period ended December 31, 2025
EMA recommended 30 veterinary medicines for marketing authorisation in 2025
This marks the second indication for which gumokimab has gained NDA review acceptance
Tatva Chintan Pharma Chem has reported total income of Rs. 133.06 crore during the period ended December 31, 2025
The RMAT designation accelerates the development of regenerative medicine therapies for serious or life-threatening diseases
The registrations grant Neurizon exclusive rights to use and defend its brand across its core operating regions
In Q3 FY26, Senores posted consolidated revenue of Rs. 175 crore, up 64% year-on-year.
Sofetabart mipitecan is a novel folate receptor alpha (FR?) antibody-drug conjugate (ADC) leveraging proprietary linker technology and an exatecan payload to target tumor cells
Subscribe To Our Newsletter & Stay Updated
